Lower Respiratory Tract Infections

The FDA accepted a biologics license application for Merck’s respiratory syncytial virus immunization, clesrovimab, the company announced Tuesday.

Another monoclonal antibody for preventing respiratory syncytial virus disease in infants could enter the market as early as next year, based on the results of two studies presented at IDWeek, Merck said.